In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Motus Gi Holdings Inc (NASDAQ: MOTS), with a price target of $10. The company’s shares closed yesterday at $7.99.
Lichtman wrote:
“We spent time on the road with MOTS management discussing latest thoughts on commercialization plans for Pure-Vu. MOTS has further focused its efforts on the in-patient market and believes its pricing potential in that market is better than initially thought. Conversations with hospital customers suggest potential disposable ASPs over $500. As a reminder, there are ~4M in-patient procedures worldwide and reimbursement in the US is in place. MOTS is focused on developing corresponding health economics data through its REDUCE study (completion 4Q18E). Our sales estimate rise on a higher ASP assumption for both disposable and workstation. Our PT rises to $10 from $7 on our higher estimates and peer multiple expansion.”
According to TipRanks.com, Lichtman is a 1-star analyst with an average return of -1.5% and a 53.9% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, Wright Medical Group, and K2M Group Holdings.
Currently, the analyst consensus on Motus Gi Holdings Inc is a Moderate Buy with an average price target of $10.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.66 and a one-year low of $3.75. Currently, Motus Gi Holdings Inc has an average volume of 107.9K.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MOTS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
